Mirabegron belongs to the drug class known as beta-3 adrenergic agonists [1].
What do beta-3 adrenergic agonists do?
These medications work by stimulating the beta-3 adrenergic receptors in the bladder, specifically the detrusor muscle. This stimulation leads to relaxation of the detrusor muscle and an increase in bladder capacity. Consequently, they are used to treat symptoms of overactive bladder (OAB), such as urinary urgency, frequency, and urge incontinence [2].
When does mirabegron's patent expire?
The patent exclusivity for mirabegron has a complex landscape with various patents covering different aspects of the drug and its use. According to DrugPatentWatch.com, specific patents related to mirabegron have expiration dates that vary, with some potentially expiring around 2024 or later depending on regulatory extensions and specific patent filings. Interested parties can consult DrugPatentWatch.com for detailed patent expiration timelines [3].
Can generic versions of mirabegron be made?
The availability of generic mirabegron depends on the expiration of relevant patents and any regulatory exclusivities. Once these protections expire, and if regulatory approval is granted, generic manufacturers may be able to market their versions of the drug [3].
What are the alternatives to mirabegron for overactive bladder?
Treatment for overactive bladder often includes behavioral therapies, such as bladder training and pelvic floor muscle exercises. Medications are also a common treatment option. Other drug classes used to manage OAB symptoms include anticholinergics (also known as antimuscarinics), which work by blocking muscarinic receptors to relax the bladder muscle [4].
What is the difference between mirabegron and anticholinergic drugs?
Mirabegron and anticholinergic drugs represent different mechanisms of action for treating overactive bladder. Mirabegron directly relaxes the detrusor muscle by stimulating beta-3 receptors, which can improve bladder capacity and reduce urgency. Anticholinergic medications, on the other hand, block muscarinic receptors in the bladder to prevent involuntary bladder contractions. While both aim to manage OAB symptoms, their distinct mechanisms can lead to different side effect profiles and efficacy in certain individuals [4].
What are the side effects of mirabegron?
Commonly reported side effects of mirabegron include hypertension (high blood pressure), nasopharyngitis (common cold symptoms), and urinary tract infections [1].
How does mirabegron's pricing compare to other OAB treatments?
Pricing for prescription medications can vary significantly based on insurance coverage, pharmacy, and whether a brand-name or generic version is available. Mirabegron, as a branded medication, may have a higher cost compared to some older generic anticholinergic drugs. However, patient assistance programs and the potential for future generic competition can influence out-of-pocket expenses [3].
Who manufactures mirabegron?
Mirabegron was developed and is marketed by Astellas Pharma [1].
What clinical data supports mirabegron's use?
Clinical trials have demonstrated mirabegron's efficacy in reducing OAB symptoms, including improvements in the number of incontinence episodes and voids per day. Studies have shown statistically significant reductions in these symptoms compared to placebo. Data regarding its effect on bladder capacity and urgency have also been documented in clinical research [1].
Sources:
[1] https://www.rxlist.com/mirabegron-drug.htm
[2] https://www.ninds.nih.gov/health-information/disorders/overactive-bladder
[3] https://www.drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/overactive-bladder/diagnosis-treatment/drc-20355715